BPC-157

Summary

• USADA states BPC-157 is not approved for human clinical use by the FDA or any other global health authority, and Józwiak and colleagues report that it has not been approved for use in standard medicine by the FDA and other global regulatory authorities.5,8 Mateescu and colleagues report that no pharmaceutical-grade formulation of it has been developed or validated.10

• On 23 July 2026, an FDA advisory committee recommended it for the compounding list by 8 votes to 6, with 1 abstention.12 The vote is non-binding, nothing has been added to the list, and the use evaluated was ulcerative colitis rather than injury recovery.4

• A 2025 systematic review screened 544 articles and included 36. Thirty-five were preclinical, one was clinical, and the review graded the whole body of work level IV and level V.1

• Three published human studies exist, none randomized, none controlled, each with 12 participants or fewer. The early ulcerative colitis work claimed by the originating Zagreb group has never been published in evaluable form, and a Phase I trial in 42 volunteers begun in 2015 had its results submission canceled in 2016.2,6,8,11

• Elimination half-life is under 30 minutes: 15.2 minutes intravenously in rats, with intramuscular bioavailability of 14–19% in rats and 45–51% in dogs.7 A 2026 review tabulates the dog intravenous figure as 5.3 minutes.10

• Animal safety work found no lethal dose from 6 μg/kg to 20 mg/kg, and no organ changes through six weeks, and nothing beyond six weeks has been tested in animals.1 The only human safety data is a two-person infusion pilot published in 2025.2

• The angiogenesis proposed as part of the healing mechanism is the same property behind the cancer concern. A 2025 review sets that argument out in detail as a prediction from mechanism, and no study has tested it.8

• Indications, dosing, frequency, and duration of treatment remain unknown.3

The Claim You Will See Most Often Is Wrong

Since late July 2026, we have repeatedly seen BPC-157 described by vendors and telehealth platforms as FDA-approved, or as newly legal. That is our own observation of the market rather than a published finding, and you should weigh it as such. Neither description is accurate. The committee vote was advisory, BPC-157 has not been added to the Section 503A Bulks List, and the indication reviewed was ulcerative colitis. What happened and what it covers is set out in the regulatory section below.

Basics and Identity

What Is BPC-157?

BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, a chain of fifteen amino acids, corresponding to a fragment of a protein found in human gastric juice.7,10

The sequence is Gly-Glu-Pro-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419 Da.7 It appears in the literature under several other names: BPC-15, PL-10, PLD-116, PL 14736 and Bepectin.7,8

Where Does the Number 157 Come From?

From the order in which it was found. Mateescu and colleagues, writing in Pharmaceutics in 2026, record that the numeral identifies the sequence as the 157th candidate compound from the original peptide screening program run by Sikiric's group at the University of Zagreb in the early 1990s.10

Fractionating gastric secretions produced a family of cytoprotective peptides. BPC-157 is the synthetic counterpart of one of them, later confirmed stable under the acidic and proteolytic conditions of the stomach.10 Mateescu and colleagues describe gastric stability as unusual and call oral delivery targeting the gastric window mechanistically justified on the strength of it.10

Is It a Drug, a Supplement or a Research Chemical?

On “approved nowhere”: this page does not present an independent survey of every national regulator. The statement rests on two sources that make it directly. USADA says BPC-157 is not approved for human clinical use by the FDA or any other global health authority,5 and Józwiak and colleagues, who report it has not been approved for use in standard medicine by the FDA and other global regulatory authorities.8 Neither publishes the jurisdiction-by-jurisdiction work behind that. If you need certainty for a specific country, check that country’s medicines regulator.

None of those categories fits, which is the source of most confusion.

It holds no drug approval from the FDA, and on the statements of the two sources above, none from any other authority either.5,8

Vasireddi and colleagues note that many BPC-157 products are sold as dietary supplements or research chemicals, which they describe as classifications not subject to FDA regulations, and that because BPC-157 is not a DEA-scheduled substance, possession is not illegal in the way possession of anabolic steroids is.1

That phrasing is looser than the law, and we would rather correct a source we cite than repeat it. Dietary supplements are FDA-regulated, under a framework separate from drugs and without premarket approval of safety and efficacy. "Research chemical" is not a regulatory classification at all. It is a label sellers apply. The accurate statement is that neither route subjects a product to the premarket review an approved drug undergoes.

The "research chemical" label is a position taken by the seller. It carries no assurance about what is in the vial.

Why Is It Called the Wolverine Peptide?

The nickname refers to the Marvel character associated with rapid healing. It is marketing language rather than a description of demonstrated effect. The word appears in none of the twelve sources behind this page.

What About BPC-157 Arginate, or Pentadeca Arginate?

None of the twelve sources behind this page characterises an arginate salt of BPC-157. Anything you read about arginate stability or potency is not coming from the papers cited here, and we will not repeat it.

What can be said: the FDA treated salt forms as distinct substances in July 2026, listing BPC-157 free base and BPC-157 acetate separately, as it did for every peptide on the agenda.4 A product that does not state its salt form is describing an incomplete identity.

Mechanism

How Does BPC-157 Work?

The proposed mechanism is that it enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines.1 Animal and in vitro data only.

In preclinical models, the same review reported improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries.1 Every one of those findings comes from animals or cell culture.

The Pathway Detail

From the 21 of 36 included studies that reported on mechanism:1

• VEGF: Stimulates vascular endothelial growth factor protein and gene expression, the pathway most commonly implicated in angiogenesis

• ERK1/2: Upregulates phosphorylation of extracellular signal-regulated kinases 1 and 2 and their downstream targets c-Fos, c-Jun and Egr-1

• AKT and KRAS: Increased AKT phosphorylation and increased KRAS gene expression

• FAK-paxillin: Increased FAK and paxillin gene expression in cultured tendon fibroblasts

• Growth hormone receptor: Increased gene and protein expression in rat tendon fibroblasts (Chang 2014)

• Nitric oxide: Upregulates NOS gene and protein expression and increases nitric oxide production

• Anti-inflammatory: Decreased COX-2 gene expression, decreased myeloperoxidase activity, decreased IL-6 and TNF-α

The review's own caution applies: these pathways are nonlinear and interconnected, and the figure summarizing them is described as a high-level overview rather than a causal chain.1

Does It Act on the Brain?

In rats, yes, in a region-specific way. Given intraperitoneally, BPC-157 increased serotonin synthesis in the substantia nigra reticulata and medial anterior olfactory nucleus, decreased it in the dorsal thalamus, hippocampus, lateral geniculate body, and hypothalamus, and blocked amphetamine-induced startle response and stereotypy.1 Rat data only.

This matters for a practical reason. It makes the mood and cognition effects people report mechanistically plausible rather than absurd, without providing any evidence that they occur in humans.

The Sikiric Group's Neurotransmitter Account, and Why to Read It Carefully

A 41-page 2024 review by Sikiric and colleagues argues that BPC-157 counteracts disturbances across dopamine, serotonin, glutamate, GABA, adrenaline/noradrenaline, acetylcholine and the nitric oxide system, including receptor blockade, over-activity, depletion, tolerance and sensitization.11 It reports an antidepressant effect in Porsolt's forced swim test with reduced immobility that, in their words, overwhelmed the effect of imipramine.11

Provenance matters here. Sikiric's group originated BPC-157 and holds patents on it, including World Patent 1998/052973 on BPC peptide salts.8 Yuan and colleagues state the consequence plainly: a considerable portion of the current evidence related to BPC-157 arises from a single research group, and independent validation of existing studies is necessary.9

The findings are not thereby wrong. They are unreplicated by independent laboratories, which is a different and specific limitation.

Pharmacokinetics

What Is the Half-Life of BPC-157?

Under 30 minutes.1,7,8 Animal data, plus one two-person human observation.

He and colleagues, publishing what they describe as the first preclinical pharmacokinetic study of BPC-157, in Frontiers in Pharmacology in 2022, measured an average elimination half-life of 15.2 minutes after a single intravenous dose in rats.7 Mateescu's 2026 review tabulates the same dataset as 15.2 minutes intravenous in rats and 5.3 minutes intravenous in dogs.10

The only retrievable human observation comes from the two-participant infusion pilot, where plasma concentrations returned to baseline within 24 hours with primary renal clearance.10 Yuan and colleagues describe that pilot as the only characterization of half-life in humans.9

One earlier human dataset is referred to but not available. Józwiak and colleagues record that the pharmacokinetic profile was estimated in humans by Veljaca and colleagues in 2002, adding that details of these studies are rather scanty.8 So the readable human record is one two-person infusion pilot reporting return to baseline within 24 hours, with no elimination half-life measured in it. The only other human pharmacokinetic work anyone refers to cannot be retrieved. Anyone quoting a human half-life figure for BPC-157 is quoting something other than a published measurement.

Full Pharmacokinetic Parameters

He's study set a proposed clinical dose of 200 µg per person per day, converting to a rat-equivalent 20 μg/kg on body surface area, and records that the effective dose of BPC-157 for treating various injuries in mice, rats and rabbits ranges from 6 to 50 μg/kg.7 Whether the milligram quantities people actually use bear any relation to those figures is addressed nowhere in the literature held.

What has never been measured in humans: volume of distribution, plasma protein binding, oral bioavailability, subcutaneous absorption kinetics, and metabolite identification.10 No data.

If the Half-Life Is 15 Minutes, Why Do People Describe Effects Lasting Days?

That gap is a recognized problem in the literature, not a detail we are inventing. Mateescu and colleagues state it directly: a plasma half-life of under 30 minutes, in their words, confirmed preclinically and in a preliminary two-subject human pilot, contrasts with prolonged biological effects lasting hours to days, a disconnect with significant implications for dosing strategy and formulation design.10

One qualification on their word “confirmed”. What the two-person pilot reports is that plasma concentrations returned to baseline within 24 hours.10 The published account of that study does not report a measured elimination half-life.2 Consistent with a short half-life is not the same as having measured one, and the only measured half-lives remain the rat and dog figures.7

Two readings are available, and neither has been tested. Either the peptide triggers downstream signalling that persists long after the molecule is gone, or the prolonged effects are not what they appear to be. Every dosing-frequency argument in circulation rests on picking one of these without evidence.

Where Does the 66 to 69 Hour Half-Life Figure Come From?

Not from any paper on this page. The figure appears in none of the twelve sources behind this entry.

It circulates widely, and we have not been able to trace it to a retrievable primary measurement. Secondary write-ups attribute it to a 1996 report of an oral dose; we have not seen that report and cannot confirm it exists in the form described, so we are not citing it. The sub-30-minute figure is the one with a published dataset behind it in two species.7 If you encounter the longer number, the burden is on whoever quotes it to produce the original.

How Long Is BPC-157 Detectable in Urine?

Four to five days.1

One study reported metabolites stable and detectable in urine for 4 days with a limit of detection of 0.1 ng/mL by high-resolution liquid chromatography mass spectrometry. Another reported limits of detection for several metabolites ranging from 0.03 to 0.11 ng/mL, detectable for 5 days by ultra-high-performance LC-MS.1 Both sit below WADA's minimum required performance level of 2 ng/mL for peptide compounds, which Vasireddi and colleagues read as analytical parameters suitable for athlete drug testing.1

One caveat we would rather state than smooth over: the review does not say what species these urine samples came from. Both underlying papers are doping-control analytical studies describing in vitro metabolism: Cox and colleagues in Drug Testing and Analysis in 2017, and Tian and colleagues on a stable isotope labeling strategy.1 Treat the 4 to 5 day window as an analytical detection capability rather than as a confirmed human excretion window.

Evidence Base and Study Quality

How Much Research Actually Exists?

36 studies met inclusion criteria in the most recent systematic review. Thirty-five were preclinical. One was clinical.1

Vasireddi and colleagues searched PubMed, Cochrane and Embase from database inception to 3 June 2024 and identified 544 articles published between 1993 and 2024.1 The review classified the resulting body of work as level IV and level V evidence, the lowest tiers of the standard hierarchy.1

The Screening Numbers, and How the 36 Break Down

PRISMA flow:1 544 records identified → 151 duplicates removed → 393 screened → 336 excluded at title and abstract → 21 full-text articles excluded → 36 included.

Topic allocation, non-mutually exclusive: 21 studies reported mechanism of action, 15 reported musculoskeletal outcomes, 3 analyzed metabolism, and 4 assessed safety profile and adverse effects.1

The safety number is the one worth sitting with, and it is smaller than four. Vasireddi's Safety Profile section states three studies; its Results section tallies four, with one reference duplicated, and following all of them back leads largely to a single 2020 preclinical safety evaluation. The trace is set out in the Safety section below.1

What Human Evidence Exists?

Three published studies, one body of unpublished trials, and one canceled trial. No published study enrolled more than 12 people. None was randomized or controlled.

There are no randomized controlled trials. The recurring problem is not only that the studies are small, but that the two datasets that would carry the most weight, the claimed phase II colitis trials and the 42-volunteer Phase I trial, were never published, so nobody outside the original teams can check them.

Why Do Sources Disagree About the Knee Study?

Nobody can say for certain, and the reconciliation we would like to give you does not survive arithmetic.

• Vasireddi 2025 reports 7 of 12 reporting improvement beyond six months following intra-articular injection of BPC-157 alone.1

• Józwiak 2025 reports 11 of 12 subjects with significant relief.8

• Yuan 2026 reports relief beyond six months for 11 participants, and adds the detail that reconciles the two: 4 of the 12 received BPC-157 combined with TB-4, of whom 3 reported significant improvement, and 1 had no relief.9

The obvious explanation is that 7-count monotherapy patients and 11-count everyone. Work it through, and it fails. If 4 of the 12 received the combination and 3 of those improved, then 8 received BPC-157 alone, and 11 total improvers requires 8 of 8 monotherapy patients to have improved, not 7.

So one of three things is true, and the reviews do not let us determine which: Vasireddi's 7 uses a denominator we cannot see, one review has miscounted, or the underlying paper is ambiguous enough to support both readings. We do not hold Lee & Padgett 2021 itself, which is where the answer lives.

Any page quoting a single figure is being more confident than three published reviews of a 12-person retrospective chart review permit. Mayfield's assessment of that same series is significant methodological flaws and a lack of controls.3

Why Did the Clinical Trials Stop?

None of the sources here records a reason, and we have not found one published.

USADA notes a concerning lack of published human clinical trial data, stating that studies appear to have been canceled or stopped without any published conclusions.5 Józwiak records the specific case: the 2015 Phase I trial in 42 volunteers had its results submission canceled in 2016.8 Vasireddi describes it as the only registered clinical trial, with unknown status since 2016.1

Absence of results is not evidence of negative results. It is also not evidence of positive ones. Neither reading is supported.

What Does the Orthopaedic Literature Conclude?

That the findings are largely unvalidated in human trials, and that nobody knows how to dose it.

Mayfield and colleagues, in the American Journal of Sports Medicine in 2026, concluded that BPC-157 demonstrated potential benefits in tendon and muscle repair, but that these findings are largely unvalidated in human trials, and that the single human case series is limited by significant methodological flaws and a lack of controls.3

Their central statement is unambiguous: information regarding the indications, dosing, frequency and duration of treatment remains unknown, and significant research on safety and efficacy is required before definitive recommendations can be made.3

Legal and Regulatory Status

What Happened in July 2026?

An advisory committee recommended seven peptides for compounding eligibility. It did not approve anything.

On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak campus in Silver Spring, Maryland, to discuss bulk drug substances nominated for the Section 503A Bulks List, which governs what substances state-licensed pharmacies may use in compounded preparations.4,12

What Was Voted on, for What Use, and by What Margin?

The use evaluated for BPC-157 was ulcerative colitis.4 Tendon repair, ligament injury, and post-surgical recovery, which are what almost all consumer interest concerns, were not the indications under review.

On the vote counts: the substances and evaluated uses come from the FDA's own published agenda.4 The vote margins do not appear in that agenda. They come from contemporaneous reporting of the meeting by Reuters, NPR, STAT, Science and others, collated in the ONPEPS July 2026 FDA explainer.12 Citing our own article is weaker than citing a primary record, and we would rather say so than let a self-citation pass as independent. Anyone needing the margins for a decision that matters should confirm them against the FDA's own meeting materials in docket FDA-2025-N-6895.

Does an Advisory Committee Vote Mean FDA Approval?

No. Three separate things are being conflated in current marketing.

• Drug approval means the FDA has reviewed a specific product for safety and efficacy for a stated indication. BPC-157 holds no such approval from the FDA, and the two reviews cited here report none from any other global authority either.5,8

• Inclusion on the 503A Bulk List would mean pharmacies may use the substance as a raw ingredient in preparations compounded against an individual prescription. Compounded preparations are not FDA-approved and are not reviewed for safety, effectiveness, or quality. The list is codified at 21 CFR 216.23 and can only be amended through formal rulemaking.12

• An advisory committee recommendation is a non-binding vote by an external panel. The FDA generally follows such recommendations but is not legally bound to.4

A recommendation to permit compounding for ulcerative colitis is three steps removed from approval of a tendon-repair drug.

What Has to Happen Next, and How Long It Takes

Two routes exist.12 Formal notice-and-comment rulemaking under the Administrative Procedure Act requires a proposed rule, a 60 to 90 day comment period, review, OMB clearance, and a final rule amending 21 CFR 216.23. Compounding-sector attorneys estimate 12 to 24 months from the vote, with no statutory deadline. Alternatively, the FDA can exercise interim enforcement discretion, measured in weeks to months.

Agency reviewers opposed every substance under consideration, citing insufficient human evidence, immunogenicity and anaphylaxis risk, and an inability to write quality standards for substances that have not been consistently defined. FDA briefing documents concluded that available studies were short in duration, small in sample size, and inadequate to establish safety or effectiveness for the reviewed indications. Five trials of BPC-157 were assessed and found insufficient.12

Sequence to date: Category 2 designation in 2023,1 withdrawal from Category 2 in April 2026, advisory recommendation in July 2026, rulemaking pending.12 The committee is scheduled to reconvene in February, which, on the reporting available, means February 2027.

Where Does That Leave Things Today?

Unchanged in law. BPC-157 has not been added to the 503A list, and USADA's current position is that there is no legal basis to include BPC-157 in any compounded medication.5

Anyone relying on the status of this question should check the FDA docket directly. The docket number is FDA-2025-N-6895.4

Sport and Drug Testing

Is BPC-157 Prohibited?

Yes, under the WADA Prohibited List in the S0 Non-Approved Substances category.5

S0 covers substances not approved for human therapeutic use by any government health authority. The July 2026 compounding discussion does not change an S0 classification, because S0 turns on approval status rather than compounding permissions.

Bans by organization and the year each was established:1 WADA specific ban 2022; UFC specific ban 2022; NFL specific ban 2022; MLB non-specific peptide hormone ban 2019; NAIA 2017; PGA 2015; NHL non-specific PED ban 2013; NCAA 1999. The NBA operates a non-specific PED ban with no year recorded.

Can an Athlete Get a Therapeutic Use Exemption?

USADA's current position is that a TUE is unlikely to be approved because permitted alternatives are available, though each application is considered case by case. Athletes are directed to complete the TUE Pre-Check Form before applying.5

An exemption normally requires a diagnosed medical need for an approved treatment. A substance holding no marketing authorization on the record of any authority identified by the sources here presents an obvious difficulty.

Safety

What Do the Animal Safety Studies Actually Show?

No lethal dose, no organ damage within six weeks, and no teratogenicity. Nothing beyond six weeks has been tested.1 Animal data only.

Vasireddi and colleagues report that three studies assessed safety and adverse effects. Across single and repeat intramuscular and intravenous doses ranging from 6 μg/kg to 20 mg/kg over six weeks, gross necropsy revealed no adverse changes in the liver, spleen, thymus or gastric wall in rat and dog models. No microscopic histopathologic changes were noted in liver, spleen, lung, kidney, brain, thymus, prostate or ovaries across similar dosing through six weeks.1

Józwiak and colleagues add the dosing granularity: 28-day administration at 4, 1 or 0.2 mg/kg/day intramuscularly in rats and 2, 0.5 or 0.1 mg/kg/day in beagle dogs produced no apparent changes compared with saline-treated animals, and a single 20 mg/kg intramuscular dose in Sprague-Dawley rats caused no deaths or abnormalities in body weight, food intake or behavior, with 10 mg/kg in beagle dogs showing no distinct adverse effects.8

On reproduction: three intramuscular injections of BPC-157 at 0.2 to 4 mg/kg were given between days 6 and 15 of rat pregnancy. After sacrifice on day 20, maternal-fetal assessment found no difference in the number of alive, dead, or aborted fetuses, and no change in mass, size, or morphology of reproductive organs and fetal tissues.1 Yuan and colleagues report the same finding.9

On genotoxicity: no change in revertant bacterial colonies in the Ames test, no chromosomal aberration in cultured mouse bone marrow cells, negative micronucleus assays.1

The limits are stated by the review itself: no study assessed adverse events beyond six weeks in animals, and as of its search cutoff of 3 June 2024, no study had assessed safety or adverse events in humans.1

That cutoff matters. The two-person intravenous pilot was published in 2025, after Vasireddi's search closed.2 It is the only study designed to assess human safety. The knee series and the interstitial cystitis pilot both report no adverse effects, but neither was built to detect them.6,9 Two participants over two days is not a safety program. Read Vasireddi's statement as accurate to June 2024, and the current position as one pilot study rather than none.

Does Injecting It with Saline or Plain Water Cause Damage at the Injection Site?

The sources contradict each other, and this is worth knowing before you read a confident answer elsewhere.

Józwiak and colleagues state that BPC 157 has been known to cause pain and/or necrosis when injected in an aqueous solution or in physiological saline, citing a 1998 patent.8 Yuan and colleagues repeat that position, attributing it to Józwiak.9

Vasireddi and colleagues report the opposite from a local tolerance study: a single injection of BPC-157 at 100 μg/mL into the quadriceps femoris of rabbits, assessed by gross necropsy, antigen excitation and anaphylaxis assays, produced no local irritation, erythema, edema, hyperemia, necrosis or ulceration over 48 hours.1 Yuan's summary of the preclinical toxicity work sits between the two, describing single and multi-dose studies in mice, rabbits, dogs and rats that did not induce significant adverse effects, though some mild local irritation manifested.9

A patent-derived claim and a controlled local tolerance study are not the same class of evidence, and the disagreement has not been resolved by anyone. Injection-site pain and swelling also appear in the user reports summarized below, where product quality is an equally available explanation.

Is There a Known Safe Dose?

No. USADA states that because BPC-157 has not been extensively studied in humans, it is unknown whether there is a safe dose, or whether there is any way to use the substance safely to treat any specific medical condition.5

The 2025 intravenous pilot reported no adverse effects at 10 mg and 20 mg in two people.2 Two participants over two days established tolerability in those two participants. It does not establish a safe dose, a safe route, or safety over months of repeated use, and both participants had used intravenous BPC-157 before enrolling.2

Does BPC-157 Cause Cancer?

No study has tested whether BPC-157 causes or promotes cancer. One oncology study exists, in a cancer cachexia model, and it was not designed to answer that question. It is described in the deeper block below. The concern is specific and mechanistically coherent, and it has been set out in the peer-reviewed literature rather than only in forums.

Józwiak and colleagues devote a section of their 2025 review to predicted consequences of the peptide's multifunctionality, explicitly framed as prediction rather than observation.8 The argument runs: BPC-157 stimulates angiogenesis; angiogenesis supplies oxygen to tumours and enables proliferation, diffusion and metastasis; BPC-157 increases VEGFR-2 expression in rats with hind limb ischemia and in endothelial cell cultures; and the VEGF family and its receptors are expressed in about half of the human cancers studied, including ovarian cancer, melanoma and thyroid cancer.8

Their conclusion, in their words: the use of BPC 157 may not be the right choice, especially in situations where we are not aware of the presence of cancer cells in our body.8

Against that, the preclinical literature reports no adverse effects across organ systems in the models tested, and BPC-157 was not mutagenic or genotoxic in vitro.1 Those models were not designed to detect tumour promotion over time, and no study ran beyond six weeks.1

The One Oncology Study, and the Other Predicted Risks

The only cancer study. Józwiak records that of all available publications, one describes an effect on cancer cachexia. BPC 157 at 10 μg/mL three times weekly intraperitoneally significantly improved total body weight in a C26 colon adenocarcinoma cachexia mouse model, and attenuated IL-6 and TNF-α expression. Tumour volume was lower in treated animals, but the difference between treated and untreated xenograft mice was not statistically significant.8

EGR-1. Elevated EGR-1 can affect tumour progression, size, prognosis and malignancy, and in prostate and gastric cancer its expression is higher than in surrounding tissue. BPC-157 upregulates Egr-1 as a downstream ERK target.1,8

Metabolites. Proline is a presumed metabolite. Proline oxidase activity depletes intracellular proline while producing superoxide, and superoxide interacts with nitric oxide to form peroxynitrite. Józwiak's conclusion is that there is no convincing certainty BPC-157 is harmless, because probable metabolites may themselves trigger downstream events.8

Nitric oxide excess. Nitric oxide at high levels inhibits heme insertion in hemoglobin, NO synthases, and heme-thiolate enzymes including cytochrome P450. Reduced CYP heme lowers activity and alters drug and xenobiotic metabolism, a plausible interaction pathway with prescription medication that has never been studied.8

Every item here is a mechanistic prediction from a review that says so. None has been measured in an animal or a person taking BPC-157. Treating them as established harms would be as wrong as ignoring them.

Can It Cause Anxiety, Panic Attacks or Mood Changes?

No published clinical study has measured psychiatric outcomes in humans.1,9 No data.

These symptoms appear in the peer-reviewed literature only as summaries of user reports. Vasireddi and colleagues record that many anonymous online users report adverse effects including injection site pain and swelling, joint pain, anxiety, panic attacks, heart palpitations, insomnia, drowsiness, weakness, fatigue, loss of appetite, depression and anhedonia.1 Yuan and colleagues list the same set and add the necessary caveat: these data are unconfirmed and ought to be treated cautiously, placed low in the evidence hierarchy.9

Both reviews offer the same two candidate explanations, and neither has been tested: unregulated production and variable dosing on one side, and the peptide's demonstrated ability to modulate inflammatory, dopamine and serotonin pathways on the other.1,9

What can be said without overreach: anyone experiencing new or worsening psychiatric symptoms while using an unapproved compound has no product-specific safety data to consult, and should involve a clinician who knows what has been taken.

Pain

Does BPC-157 Work as a Painkiller?

Not in the way that word is usually meant, on animal evidence.8,9 Rat and mouse data only.

• Formalin test. BPC-157 decreased flinching during acute phase 1 but not persistent phase 2 pain.9 Józwiak describes the antinociceptive activity in this model as only partial.8

• Surgical incision. Local application at incision sites significantly raised the pain threshold at early time points hours after injury, with the reduced sensitivity lessened by 7 days post-surgery.9

• Hot-plate test. Ineffective in healthy animals on a hot plate maintained at 55 °C.8

The reading researchers take from this pattern is that any pain relief comes from an anti-inflammatory mechanism producing short-lived alleviation, rather than a centrally mediated analgesic effect.9

Does It Interact with Morphine or Other Analgesics?

One animal finding says yes, and it points the wrong way for anyone hoping to stack them.

Injected intraperitoneally into mice given morphine, BPC 157 behaved similarly to naloxone: morphine-induced analgesia was reduced to the levels recorded in control saline mice.8

That is a single animal finding, never examined in humans, and it is the only published signal of an interaction with a common analgesic. Józwiak's own conclusion is that more studies are needed to determine which types of pain the compound acts on and where in pain processing it acts.8

Product Quality and Formulation

Why Does Product Quality Dominate This Topic?

Because no pharmaceutical-grade formulation of BPC-157 has been developed or validated, according to Mateescu and colleagues' assessment.10

The channels we are aware of are compounding pharmacies operating without a lawful basis for this substance,5 and vendors selling material labeled for research. We have not surveyed every route a vial can reach a buyer, and neither of those two offers a verified product. Mateescu and colleagues record that BPC-157 lacks BCS classification data, permeability characterization, and formal excipient compatibility studies, and that its approved route of administration is none.10

Vasireddi and colleagues put a number on the general contamination problem: between 12% and 58% of ergo-nutritional supplements are contaminated with other, often unsafe, substances.1 Product risk and pharmacological risk are separate problems, and both are live.

What Is a Certificate of Analysis and What Can It Prove?

It reports laboratory results for a specific batch, usually identity and purity. Two limits apply.

This subsection and the one below describe standard analytical practice rather than findings from the twelve papers cited on this page. They carry no superscripts because none of those papers is their source.

It describes the batch tested, which may not be the vial received. And its value depends on a chain of custody between laboratory, seller, and buyer that an end purchaser cannot independently verify.

What Is the Difference Between Purity and Identity Testing?

Purity analysis, typically by HPLC, estimates what proportion of a sample is the intended compound. Identity testing, typically by mass spectrometry, addresses whether the molecule present is the molecule claimed, though a mass match alone does not fully establish structure, and sequencing methods such as tandem MS are what confirm the amino acid order.

A sample can be high purity and still be the wrong compound. A certificate reporting purity alone does not establish identity. The FDA made the same point at the July 2026 meeting from the regulator's side: quality standards cannot be written for a substance that has not been consistently defined, and compounds sold under a single peptide name vary considerably in chemical composition.12

What the Sequence Itself Tells You About Stability

Mateescu and colleagues analyzed BPC-157 as a formulation problem rather than a pharmacology one, and the result is more useful than most storage advice in circulation.10

What remains unknown: physical stability, aggregation, and adsorption to container surfaces are uncharacterized, and no forced degradation study under ICH Q1A stress conditions (acid, base, oxidative, thermal, photolytic) has been performed.10 No data.

Reconstitution, Storage and Handling

What Is Bacteriostatic Water?

Sterile water containing a preservative, usually benzyl alcohol, which inhibits bacterial growth and permits a vial to be entered more than once. Sterile water contains no preservative and is intended for single use.

Does BPC-157 Need Refrigeration?

There is no validated answer, and the reason is structural rather than an oversight.

No approved or pharmaceutical-grade BPC-157 product exists, so no manufacturer has run the stability program that produces a storage specification, and no vendor's preparation has published stability data.10

What the sequence analysis supports: the oxidative degradation routes that make many peptides temperature- and light-sensitive are absent here, since BPC-157 contains no methionine, cysteine or tryptophan.10 The live chemical risk is hydrolysis at the Asp10–Asp11 junction under mildly acidic and neutral conditions, which is a solution-state problem rather than a powder-state one.10 Aggregation and adsorption remain uncharacterized.10

Storage advice circulating in communities is extrapolated from other peptides. That extrapolation is now partly checkable against sequence-level analysis, and partly not.

Where the Dosing Detail Lives

Reconstitution volumes, dose ranges, frequency and cycle length are covered in the ONPEPS dosage guide, which documents what is actually being used and where those figures came from. Mayfield and colleagues state that indications, dosing, frequency and duration of treatment remain unknown,3 so nothing in circulation is a validated schedule.

Non-Response

Why Do Some People Report Nothing at All?

No study has examined non-response, so there is no evidence-based answer. What can be laid out honestly is the list of candidate explanations, none of which can be ranked without controlled data.

• The product may not contain what the label claims, in identity or in quantity. Vasireddi cites contamination rates of 12% to 58% for ergogenic-nutritional supplements as a category; no equivalent figure exists for BPC-157 products specifically. 1

• The injury may not be the type any regenerative signal would address, such as structural nerve compression rather than connective tissue damage

• Expectations may be set against animal-model timelines. The rat MCL study read out at 90 days post-transection, and the Achilles studies over shorter windows still, which are not human tendon-healing timescales1

• Concurrent rehabilitation may be absent

• The compound may not work for that presentation, or at all, in humans

That last possibility is the one most likely to go unmentioned by anyone selling the compound. With 35 preclinical studies, one flawed clinical series and no randomized trial, it remains fully open.1,3

Where the Observational Record Fits

ONPEPS maintains an observational dataset of documented BPC-157 use cases, analyzed across the linked deep-dive articles. That dataset records what people did and what they reported.

Its value is in surfacing patterns no trial has looked for. Its limit is structural and worth stating each time it is used: self-reported, uncontrolled, unblinded, subject to natural healing, concurrent rehabilitation, placebo response, and selective reporting. Vasireddi graded the published literature level IV and level V.1 No formal hierarchy assigns a position to a dataset like ours, so treat this as our own judgment rather than a classification: it belongs below the published preclinical work, not alongside it.

The overlap between what the animal literature predicts and what users describe is real. It is not confirmation.

Related ONPEPS Coverage

• Dosage, protocols, frequency and cycle length

• Tendon repair, shoulder, tennis elbow and Achilles recovery

• Brain-gut axis, gut integrity and inflammatory signalling

• TB-500 versus BPC-157 and the Wolverine stack

• FDA peptide actions, July 2026

References

1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. Open access. PMID 40756949. pubmed.ncbi.nlm.nih.gov/40756949

2. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. Free article. PMID 40131143. pubmed.ncbi.nlm.nih.gov/40131143

3. Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Hatch GFR, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. Paywalled; abstract consulted. PMID 41476424. pubmed.ncbi.nlm.nih.gov/41476424

4. US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Agenda, evaluated uses and advisory committee status. Agenda published 22 July 2026. Docket FDA-2025-N-6895. fda.gov

5. United States Anti-Doping Agency. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide. Accessed 11 August 2026. usada.org

6. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560. pubmed.ncbi.nlm.nih.gov/39325560

7. He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. Pharmacokinetics, Distribution, Metabolism, and Excretion of Body-Protective Compound 157, a Potential Drug for Treating Various Wounds, in Rats and Dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. pmc.ncbi.nlm.nih.gov/articles/PMC9794587

8. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. Open access. PMID 40005999. mdpi.com/1424-8247/18/2/185

9. Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, Amirdelfan K, Burke HW, Christo PJ, Robinson CL. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6):2876. Open access. doi.org/10.3390/ijms27062876

10. Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, Popa MD, Iurciuc S, Muresan CO, Enache A. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. Open access. PMID 42198317. doi.org/10.3390/pharmaceutics18050625

11. Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461. Open access. Authored by the group that originated BPC-157; read with that in mind. doi.org/10.3390/ph17040461

12. ONPEPS. FDA Peptide News July 2026: The Only Source You Need. Published 6 August 2026. Self-citation, cited eight times on this page. Used for vote margins, venue, the 21 CFR 216.23 rulemaking routes, the FDA reviewers' objections, the five BPC-157 trials assessed, the April 2026 Category 2 withdrawal and the February reconvening. That article sources these to the FDA meeting agenda, FDA briefing documents and contemporaneous reporting by Reuters, NPR, STAT, Science, AJMC and ABC News. Treat as a collation of those sources rather than as primary, and go to the docket for anything load-bearing. onpeps.com

Not Medical Advice

BPC-157 holds no marketing authorization for human use on the record of any authority identified by the sources on this page; no safe human dose has been established, and it is prohibited in sport. Consult a qualified healthcare provider before acting on anything here.

Literature and regulatory sources verified 11 August 2026. The FDA had not published an outcome for the July 2026 advisory recommendation as of that date. Regulatory status on this compound is changing and should be re-verified against docket FDA-2025-N-6895 before relying on any statement here. Where a figure is marked Animal data only. it has never been measured in a human; where marked No data. it has never been measured at all.